Subcutaneous Allergen-Specific Immunotherapy Is Safe in Pediatric Patients with Allergic Rhinitis

Conclusions: The SCIT is safe in pediatric patients. The ADVrs are infrequent, grade 1 being the most reported; however, at #x3e;12 weeks, the risk of ADVrs that involve 2 organs systems increases.Int Arch Allergy Immunol

https://www.karger.com/Article/FullText/513158

Source: International Archives of Allergy and Immunology - February 19, 2021 Category: Allergy & Immunology Source Type: research